SCHEMBL1258348

SCHEMBL1258348

CCCC(=O)c1sc(NC(=O)c2ccco2)nc1-c1ccco1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 8/20 0.80
ADORA1 P30542 7/20 0.80
L3MBTL1 Q9Y468 2/20 0.66
HSP90AA1 P07900 1/20 0.66
RAB9A P51151 3/20 0.58
HPGD P15428 3/20 0.58
NPC1 O15118 2/20 0.58
PPARG P37231 3/20 0.58
KDM4E B2RXH2 2/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
NCOA2 Q15596 2/20 0.58
NPSR1 Q6W5P4 2/20 0.58
RXFP1 Q9HBX9 2/20 0.58
NCOA1 Q15788 1/20 0.58
ALDH1A1 P00352 2/20 0.57
PKM P14618 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
MAPT P10636 1/20 0.55
NFKB1 P19838 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1256400 0.87 ADORA2A (0.65) ADORA2AADORA1L3MBTL1HSP90AA1RAB9A
SCHEMBL1256204 0.86 ADORA2A (0.61) ADORA2AADORA1L3MBTL1HSP90AA1RAB9A
SCHEMBL1256401 0.84 KDM4E (0.62) ADORA2AADORA1L3MBTL1HSP90AA1RAB9A
SCHEMBL1255598 0.81 ADORA2A (0.57) ADORA2AADORA1L3MBTL1HSP90AA1RAB9A
SCHEMBL1254738 0.80 ADORA2A (0.55) ADORA2AADORA1L3MBTL1HSP90AA1RAB9A
SCHEMBL1255930 0.79 ADORA2A (0.53) ADORA2AADORA1L3MBTL1HSP90AA1RAB9A
SCHEMBL1255522 0.79 ALDH1A1 (0.52) ADORA2AADORA1L3MBTL1RAB9AHPGD
SCHEMBL1254666 0.78 ALDH1A1 (0.56) ADORA2AADORA1RAB9AHPGDNPC1
SCHEMBL1257002 0.78 ADORA2A (0.59) ADORA2AADORA1L3MBTL1HSP90AA1RAB9A
SCHEMBL1256251 0.78 L3MBTL1 (0.54) ADORA2AADORA1L3MBTL1HSP90AA1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1921077-B1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-26 EP disclosed
EP-3002283-B1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO LTD (JP) 2017-06-14 EP disclosed
EP-3002283-A1 THIAZOLE DERIVATIVES Kyowa Hakko Kirin Co., Ltd. (JP) 2016-04-06 EP disclosed
EP-1700856-B1 THIAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2015-11-11 EP disclosed
US-8889718-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-11-18 US disclosed
US-20130267509-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-10-10 US disclosed
US-8420827-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-04-16 US disclosed
US-20110105486-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-05-05 US disclosed
US-7928098-B2 Therapeutic and/or preventive agents for a sleep disorder KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-19 US disclosed
US-7880013-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-01 US disclosed
US-20100256361-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
US-7718808-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-05-18 US disclosed
EP-1921077-A1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-14 EP disclosed
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-10 US disclosed
EP-1700856-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267509-A1 THIAZOLE DERIVATIVES THRA, CHD8, CYP2C8 ADORA2A 450/4885ADORA1 954/4885L3MBTL1 436/4885
US-20110105486-A1 THIAZOLE DERIVATIVES CHD8, CYP2C8, THRA ADORA2A 392/4885ADORA1 720/4885L3MBTL1 702/4885
US-20100256361-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885L3MBTL1 2618/4885
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885L3MBTL1 2473/4885
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER HCRTR1, MTNR1A, HCRTR2 ADORA2A 525/4885ADORA1 353/4885L3MBTL1 1732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.